The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
The Emerging Evidence of the Parkinson Pandemic
Open accessAbstract
Neurological disorders are now the leading source of disability globally, and the fastest growing neurological disorder in the world is Parkinson disease. From 1990 to 2015, the number of people with Parkinson disease doubled to over 6 million. Driven principally by aging, this number is projected to double again to over 12 million by 2040. Additional factors, including increasing longevity, declining smoking rates, and increasing industrialization, could raise the burden to over 17 million. For most of human history, Parkinson has been a rare disorder. However, demography and the by-products of industrialization have now created a Parkinson pandemic that will require heightened activism, focused planning, and novel approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Feigin, V. L., Nichols, E., Alam, T., Bannick, M. S., Beghi, E., Blake, N., Culpepper, W. J., Dorsey, E. R., Elbaz, A., Ellenbogen, R. G., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30499-x · Cited by 5,644
Self-citationCaregiving as a Risk Factor for Mortality: The Caregiver Health Effects Study
Schulz, R., & Beach, S. R. (1999) · JAMA · doi:10.1001/jama.282.23.2215 · Cited by 3,340 · cited 1×
“The strain of caregiving has adverse health consequences of its own [29].”
BackgroundDorsey, E. R., Elbaz, A., Nichols, E., Abbasi, N., Abd-Allah, F., Abdelalim, A., Adsuar, J. C., Ansha, M. G., Brayne, C., Choi, J.-Y. J., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30295-3 · Cited by 2,816
Self-citationProjected number of people with Parkinson disease in the most populous nations, 2005 through 2030
Dorsey, E. R., Constantinescu, R., Thompson, J. P., Biglan, K. M., Holloway, R. G., Kieburtz, K., Marshall, F. J., Ravina, B. M., Schifitto, G., Siderowf, A., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000247740.47667.03 · Cited by 2,472
Self-citationFeigin, V. L., Abajobir, A. A., Abate, K. H., Abd-Allah, F., Abdulle, A. M., Abera, S. F., Abyu, G. Y., Ahmed, M. B., Aichour, A. N., Aichour, I., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30299-5 · Cited by 2,275
Self-citationMurray, C. J. L., Barber, R. M., Foreman, K. J., Ozgoren, A. A., Abd-Allah, F., Abera, S. F., Aboyans, V., Abraham, J. P., Abubakar, I., Abu-Raddad, L. J., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)61340-x · Cited by 1,964
Self-citationIncidence of Parkinson's Disease: Variation by Age, Gender, and Race/Ethnicity
Van Den Eeden, S. K. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg068 · Cited by 1,747
Parkinson, J. (2002) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.14.2.223 · Cited by 1,628
The Parkinson Pandemic—A Call to Action
Dorsey, E. R., & Bloem, B. R. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2017.3299 · Cited by 1,091
Self-citationUS spending on personal health care and public health, 1996-2013.
Dieleman, J. L., Baral, R., Birger, M., Bui, A. L., Bulchis, A., Chapin, A., Hamavid, H., Horst, C., Johnson, E. K., Joseph, J., et al. (2016) · JAMA · doi:10.1001/jama.2016.16885 · Cited by 1,044
Cited by
Bloem, B. R., Okun, M. S., & Klein, C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00218-x · Cited by 3,920
Self-citationChallenges in the diagnosis of Parkinson's disease
Tolosa, E., Garrido, A., Scholz, S. W., & Poewe, W. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00030-2 · Cited by 1,874
The global burden of neurological disorders: translating evidence into policy
Feigin, V. L., Vos, T., Nichols, E., Owolabi, M. O., Carroll, W. M., Dichgans, M., Deuschl, G., Parmar, P., Brainin, M., & Murray, C. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30411-9 · Cited by 1,303
Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology
Simon, D. K., Tanner, C. M., & Brundin, P. (2020) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2019.08.002 · Cited by 1,114
“As the global population ages, PD prevalence is expected to increase dramatically, doubling in the next two decades(8).”
BackgroundThe epidemiology of Parkinson's disease
Ben-Shlomo, Y., Darweesh, S., Llibre-Guerra, J., Marras, C., San Luciano, M., & Tanner, C. (2024) · The Lancet · doi:10.1016/s0140-6736(23)01419-8 · Cited by 967
Current and projected future economic burden of Parkinson’s disease in the U.S.
Yang, W., Hamilton, J. L., Kopil, C., Beck, J. C., Tanner, C. M., Albin, R. L., Ray Dorsey, E., Dahodwala, N., Cintina, I., Hogan, P., et al. (2020) · npj Parkinson's Disease · doi:10.1038/s41531-020-0117-1 · Cited by 657
Genetics and Pathogenesis of Parkinson's Syndrome
Ye, H., Robak, L. A., Yu, M., Cykowski, M., & Shulman, J. M. (2023) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-031521-034145 · Cited by 416
Genetics of Parkinson's disease: An introspection of its journey towards precision medicine
Bandres-Ciga, S., Diez-Fairen, M., Kim, J. J., & Singleton, A. B. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104782 · Cited by 370
Incidence of Parkinson disease in North America
Willis, A. W., Roberts, E., Beck, J. C., Fiske, B., Ross, W., Savica, R., Van Den Eeden, S. K., Tanner, C. M., Marras, C., on behalf of the Parkinson’s Foundation P4 Group, et al. (2022) · npj Parkinson's Disease · doi:10.1038/s41531-022-00410-y · Cited by 341
Metagenomics of Parkinson’s disease implicates the gut microbiome in multiple disease mechanisms
Wallen, Z. D., Demirkan, A., Twa, G., Cohen, G., Dean, M. N., Standaert, D. G., Sampson, T. R., & Payami, H. (2022) · Nature Communications · doi:10.1038/s41467-022-34667-x · Cited by 346
Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent
Mehdi, S. F., Pusapati, S., Anwar, M. S., Lohana, D., Kumar, P., Nandula, S. A., Nawaz, F. K., Tracey, K., Yang, H., LeRoith, D., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1148209 · Cited by 317
Digital colloid-enhanced Raman spectroscopy by single-molecule counting
Bi, X., Czajkowsky, D. M., Shao, Z., & Ye, J. (2024) · Nature · doi:10.1038/s41586-024-07218-1 · Cited by 305
Yang, Y., Yuan, Y., Zhang, G., Wang, H., Chen, Y.-C., Liu, Y., Tarolli, C. G., Crepeau, D., Bukartyk, J., Junna, M. R., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01932-x · Cited by 296
Anionic nanoplastic contaminants promote Parkinson’s disease–associated α-synuclein aggregation
Liu, Z., Sokratian, A., Duda, A. M., Xu, E., Stanhope, C., Fu, A., Strader, S., Li, H., Yuan, Y., Bobay, B. G., et al. (2023) · Science Advances · doi:10.1126/sciadv.adi8716 · Cited by 262
Gut Microbiota: A Novel Therapeutic Target for Parkinson’s Disease
Zhu, M., Liu, X., Ye, Y., Yan, X., Cheng, Y., Zhao, L., Chen, F., & Ling, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.937555 · Cited by 177
Huang, P., Zhang, Z., Zhang, P., Feng, J., Xie, J., Zheng, Y., Liang, X., Zhu, B., Chen, Z., Feng, S., et al. (2024) · Molecular Neurobiology · doi:10.1007/s12035-023-03713-0 · Cited by 111
Recent Research Trends in Neuroinflammatory and Neurodegenerative Disorders
Cohen, J., Mathew, A., Dourvetakis, K. D., Sanchez-Guerrero, E., Pangeni, R. P., Gurusamy, N., Aenlle, K. K., Ravindran, G., Twahir, A., Isler, D., et al. (2024) · Cells · doi:10.3390/cells13060511 · Cited by 103
“Other risk factors that contribute to the development of PD include advanced age, longevity, and industrial by-products and decreasing smoking rates [50].”
BackgroundPotential roles of gut microbiota and microbial metabolites in Parkinson’s disease
Zheng, S.-Y., Li, H.-X., Xu, R.-C., Miao, W.-T., Dai, M.-Y., Ding, S.-T., & Liu, H.-D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101347 · Cited by 101
Mitochondrial dysfunction in astrocytes: A role in Parkinson’s disease?
Bantle, C. M., Hirst, W. D., Weihofen, A., & Shlevkov, E. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.608026 · Cited by 95
Adaptive Neuroplasticity in Brain Injury Recovery: Strategies and Insights
Zotey, V., Andhale, A., Shegekar, T., & Juganavar, A. (2023) · Cureus · doi:10.7759/cureus.45873 · Cited by 88
A prebiotic diet modulates microglial states and motor deficits in α-synuclein overexpressing mice
Abdel-Haq, R., Schlachetzki, J. C., Boktor, J. C., Cantu-Jungles, T. M., Thron, T., Zhang, M., Bostick, J. W., Khazaei, T., Chilakala, S., Morais, L. H., et al. (2022) · eLife · doi:10.7554/elife.81453 · Cited by 82
Inflammasome assembly in neurodegenerative diseases
Singh, J., Habean, M. L., & Panicker, N. (2023) · Trends in Neurosciences · doi:10.1016/j.tins.2023.07.009 · Cited by 83
Limitations of human brain organoids to study neurodegenerative diseases: a manual to survive
Urrestizala-Arenaza, N., Cerchio, S., Cavaliere, F., & Magliaro, C. (2024) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2024.1419526 · Cited by 80
Tsao, S.-P., Nurrahma, B. A., Kumar, R., Wu, C.-H., Yeh, T.-H., Chiu, C.-C., Lee, Y.-P., Liao, Y.-C., Huang, C.-H., Yeh, Y.-T., et al. (2021) · Antioxidants · doi:10.3390/antiox10111823 · Cited by 79
Khan, M. R., Yin, X., Kang, S.-U., Mitra, J., Wang, H., Ryu, T., Brahmachari, S., Karuppagounder, S. S., Kimura, Y., Jhaldiyal, A., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.add0499 · Cited by 64
Advances in diagnosis, classification, and management of pain in Parkinson's disease
Tinazzi, M., Gandolfi, M., Artusi, C. A., Bannister, K., Rukavina, K., Brefel-Courbon, C., de Andrade, D. C., Perez-Lloret, S., & Mylius, V. (2025) · The Lancet Neurology · doi:10.1016/s1474-4422(25)00033-x · Cited by 60
Extracellular Vesicles as Novel Diagnostic and Prognostic Biomarkers for Parkinson’s Disease
Leggio, L., Paternò, G., Vivarelli, S., Falzone, G. G., Giachino, C., Marchetti, B., & Iraci, N. (2021) · Aging and disease · doi:10.14336/ad.2021.0527 · Cited by 55
Neuroprotective effects of Withania somnifera in the SH-SY5Y Parkinson cell model
Wongtrakul, J., Thongtan, T., Kumrapich, B., Saisawang, C., & Ketterman, A. J. (2021) · Heliyon · doi:10.1016/j.heliyon.2021.e08172 · Cited by 52
Pan, S., Wei, H., Yuan, S., Kong, Y., Yang, H., Zhang, Y., Cui, X., Chen, W., Liu, J., & Zhang, Y. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.1022879 · Cited by 51
Watanabe, H., Dijkstra, J. M., & Nagatsu, T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042009 · Cited by 48
Stephenson, D., Hill, D., Cedarbaum, J. M., Tome, M., Vamvakas, S., Romero, K., Conrado, D. J., Dexter, D. T., Seibyl, J., Jennings, D., et al. (2019) · Journal of Parkinson’s Disease · doi:10.3233/jpd-191648 · Cited by 46
“Parkinson’s disease (PD) is the second most common neurodegenerative disease affecting 2% to 3% of people over 65 years of age [1] and has been recently reported to be the most rapidly growing neurological disease [2, 3].”
BackgroundKulcsarova, K., Bang, C., Berg, D., & Schaeffer, E. (2023) · Journal of Parkinson’s Disease · doi:10.3233/jpd-230206 · Cited by 40
“However, the export to other countries, including African countries, India, Australia, or the United States, continues [7].”
BackgroundAlternative platelet activation pathways and their role in neurodegenerative diseases
Ferrer-Raventós, P., & Beyer, K. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105512 · Cited by 39
Challenges of Repurposing Tetracyclines for the Treatment of Alzheimer’s and Parkinson’s Disease
Markulin, I., Matasin, M., Turk, V. E., & Salković-Petrisic, M. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-021-02457-2 · Cited by 36
Heart Matters: Cardiac Dysfunction and Other Autonomic Changes in Parkinson’s Disease
Gonçalves, V. C., Cuenca-Bermejo, L., Fernandez-Villalba, E., Martin-Balbuena, S., da Silva Fernandes, M. J., Scorza, C. A., & Herrero, M.-T. (2022) · The Neuroscientist · doi:10.1177/1073858421990000 · Cited by 37
A review of studies on gut microbiota and levodopa metabolism
Zhong, Z., Ye, M., & Yan, F. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1046910 · Cited by 31
Endosomal sorting pathways in the pathogenesis of Parkinson's disease
(2020) · Progress in Brain Research · doi:10.1016/bs.pbr.2020.02.001 · Cited by 25
Kwon, H., Clifford, G. D., Genias, I., Bernhard, D., Esper, C. D., Factor, S. A., & McKay, J. L. (2023) · Sensors · doi:10.3390/s23041766 · Cited by 24
Bounsall, K., Milne-Ives, M., Hall, A., Carroll, C., & Meinert, E. (2023) · JMIR Research Protocols · doi:10.2196/46581 · Cited by 16
New Perspectives in Nonintrusive Sleep Monitoring for Neurodegenerative Diseases—A Narrative Review
Masi, G., Amprimo, G., Priano, L., & Ferraris, C. (2023) · Electronics · doi:10.3390/electronics12051098 · Cited by 6
AI-enabled Parkinson's disease screening using smile videos
Adnan, T., Islam, M. S., Lee, S., Wasifur Rahman Chowdhury, E. M., Tithi, S. D., Noshin, K., Islam, M. R., Sarker, I., Rahman, M. S., Schneider, R. B., et al. (2025) · NEJM AI · doi:10.1056/aioa2400950 · Cited by 5
Self-citationHeo, E.-J., Lee, Y., Hyung Seo, M., & Yeo, S. (2023) · Neuroscience Letters · doi:10.1016/j.neulet.2023.137464 · Cited by 5
Quantifying Device Type and Handedness Biases in a Remote Parkinson's Disease AI‐Powered Assessment
Tumpa, Z. N., Zawad, M. R. S., Sollis, L., Parab, S., Chen, I. Y., & Washington, P. (2025) · npj Digital Medicine · doi:10.1038/s41746-025-01934-2 · Cited by 4
Ayala, D. A., Hall, G. M., Das, D., Tijerina, E., Villagran, L. L., Khan, Z., Paliwal, D., Anand, A., Rimer, M., & Srinivasan, R. (2026) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-026-01713-x · Cited by 1
“Parkinson’s disease (PD) is the fastest growing neurological disorder (Dorsey et al. 2018; Su et al. 2025) with no known cure.”
Khan, M. R., Yin, X., Kang, S.-U., Mitra, J., Wang, H., Brahmachari, S., Karuppagounder, S. S., Kimura, Y., Jhaldiyal, A., Kim, H. H., et al. (2022) · doi:10.1101/2022.10.03.510455
Metadata
- Authors
- Dorsey, E. R., Sherer, T., Okun, M. S., & Bloem, B. R.
- Venue
- Journal of Parkinson’s Disease
- Publisher
- SAGE Publications
- Published
- 2018-12-18
- Volume
- 8
- Issue
- s1
- Pages
- S3-S8
- ISSN
- 1877-7171 (ISSN-L)
- 1877-718X
- OpenAlex
- W2904404980
- Cited by
- 1,977
- References
- 26
- FWCI
- 42.09
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.